Biofilms are pervasive and represent the most prevalent bacterial mode of growth. The current global market for wound care management technology is estimated at US $4.5 billion per year.
Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as an effective shield against attack.
This resiliency contributes to human health related problems such as tooth decay, inflammatory skin disorders, outbreaks of food-borne illnesses, hospital acquired “superbug” infections, medical device and recurrent urinary tract associated infections, and chronic wounds. According to the USA National Institutes of Health (NIH) biofilms are estimated to be responsible for 80% of all human bacterial infections and are costly to deal with for consumers, industry, governments and hospitals. The healing of chronic wounds alone costs the United States health care system $20 Billion per year.
“The in-vivo efficacy of catheters coated with this unique antimicrobial/antibiofilm composition prompts clinical evaluation of such an innovative approach”.
– Dr. Rabih Darouiche, Baylor College of Medicine, Houston, Texas
Human Health Products
Kane Biotech has a number of DispersinB® formulations in development including formulations with antibiotics and the antibiofilm enzyme β-N-Acetylglucosaminidase.
Kane Biotech has developed antibiofilm technology in combination with Gentamycin and formulated an Enzyme-Gentamycin wound gel spray containing a thermo reversible gelling agent that makes the liquid spray become a gel when applied at body temperature. Kane continues to evaluate and develop cutting edge technologies independently, and in cooperation with leading academic institutions.
In addition, shampoos and skin care formulations for human skin infections such as seborrheic dermatitis are in development.